Primary Sjögren's syndrome treated with Efamol/Efavit. A double-blind cross-over investigation.
Thirty-six patients with primary Sjögren's syndrome participated in a randomised double-blind, cross-over, 3-week, study to compare the effect of Efamol (1500 mg X 2) with that of placebo. Efamol contains 9% of the prostaglandin-E1 precursor gamma-linolenic acid, which is presumed to occur in reduced levels in Sjögren's syndrome. Efamol treatment improved the Schirmer-I-test (P less than 0.03) while values of break-up time,-van Bijsterveld score, corneasensitivity, tear-lysozyme and nuclear chromatin in conjunctival epithelial cells did not reach the statistical 0.05 level.
D000328:Adult; D000368:Aged; D001205:Ascorbic Acid / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D005228:Fatty Acids, Essential; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use*; D005260:Female; D005483:Flushing / Q000209:etiology; D006801:Humans; D008041:Linoleic Acids; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000009:adverse effects / Q000627:therapeutic use*; D031665:Oenothera biennis; D010938:Plant Oils; D011736:Pyridoxine / Q000627:therapeutic use*; D012859:Sjogren's Syndrome / Q000188:drug therapy*; D015032:Zinc / Q000627:therapeutic use*; D017967:Zinc Compounds; D017965:gamma-Linolenic Acid
D004338:Drug Combinations; D005228:Fatty Acids, Essential; D005231:Fatty Acids, Unsaturated; D008041:Linoleic Acids; D010938:Plant Oils; D017967:Zinc Compounds; D009525:Niacin; C028498:evening primrose oil; D017965:gamma-Linolenic Acid; C038070:efavit; D015032:Zinc; D011736:Pyridoxine; D001205:Ascorbic Acid